Logo
JuveLook 1 x 50 mg

JuveLook 1 x 50 mg

JUVELOOK

Skin booster / tissue stimulator
  • Certified as a Class III implantable medical device with CE marking for use as a hybrid collagen stimulator (PDLLA + HA).
  • Approved by the Korean Ministry of Food and Drug Safety (KFDA/MFDS) as a PDLLA Based skin booster.
  • Manufacturer technology based on patented PDLLA reticular particle structure designed to enhance safety and effectiveness.
  • Produced under quality management systems compliant with international medical device standards (e.g. ISO 13485) as stated by manufacturer and distributors.
  • Marketed in multiple countries via authorised distributors, with awards including recognition at international aesthetic congresses for injectable skin revitalisation.
Hybrid PDLLA + hyaluronic acid collagen-stimulating biostimulator

Description

JuveLook 1 x 50 mg is an advanced hybrid dermal biostimulator and skin booster combining ultrafine Poly-D,L-lactic acid (PDLLA) microspheres with non-crosslinked hyaluronic acid (HA). Supplied as a single 50 mg lyophilised powder vial to be reconstituted before injection, it provides an immediate hydrating and plumping effect from HA together with long-term stimulation of collagen and elastin production driven by PDLLA. Designed for delicate and challenging areas including the periorbital region, face, neck and décolleté, JuveLook improves skin texture, elasticity and firmness, softens fine lines and acne scars and addresses early volume loss while maintaining a very natural look and feel when administered by trained medical professionals.

Bnefits

  • Hybrid PDLLA + HA formulation delivers both immediate hydration and long-term collagen stimulation.
  • Improves skin texture, tone and elasticity while gently firming lax or crepey skin.
  • Reduces the appearance of fine lines, superficial wrinkles and acne scars.
  • Helps correct volume loss in delicate areas such as tear troughs, lower eyelids and temples without a heavy filler look.
  • Provides gradual, natural-looking rejuvenation with low risk of over-correction.
  • Small-particle PDLLA (typically ~20–50 µm) designed for safer, smoother injection and reduced risk of palpable nodules.
  • Long-lasting effects, commonly 12–18 months and in many protocols reported up to around 24 months after a full course.
  • CE- and KFDA-approved hybrid collagen stimulator with a patented PDLLA reticular structure aimed at improved safety profile.
  • Suitable for a wide range of treatment areas including face, neck, décolleté and hands when used with appropriate technique.

Indications

  • Biostimulatory skin booster for improvement of skin texture, elasticity and firmness.
  • Treatment of fine lines and superficial wrinkles in the face, periorbital region, neck and décolleté.
  • Softening of atrophic and acne scars and improvement of skin surface irregularities.
  • Rejuvenation of the eye area including dark circles, marked tear troughs and volume loss in the lower eyelid area.
  • Management of early volume loss and mild laxity in sensitive areas such as forehead, temples and periorbital region.
  • Overall skin revitalisation and prevention-oriented collagen stimulation in patients showing early signs of ageing.
  • Indicated for use as a tissue stimulator/skin booster in adults, administered by qualified medical professionals only.

Composition

  • Total lyophilised powder content: 50 mg per vial.
  • Poly-D,L-lactic acid (PDLLA): approximately 42.4–42.5 mg – biodegradable, biostimulatory polymer inducing collagen synthesis.
  • Non-crosslinked hyaluronic acid (HA): 7.5 mg – provides immediate hydration and subtle plumping after reconstitution and injection.
  • Excipients: buffer components and stabilisers suitable for lyophilised injectable medical devices (full qualitative list in official IFU).
  • To be reconstituted with 2–3 ml of sterile physiological saline (0.9% NaCl) before administration, according to protocol.

Formulation

  • Lyophilised (freeze-dried) powder in a sterile glass vial containing PDLLA microspheres and non-crosslinked HA.
  • Hybrid biostimulator combining immediate HA-driven hydration with time-released PDLLA collagen stimulation.
  • PDLLA particles typically in the 20–50 µm range, with a patented porous reticular structure designed for improved biocompatibility and controlled degradation.
  • Designed to be reconstituted with sterile saline immediately prior to injection to form a smooth injectable suspension.
  • Single-use, preservative-free, sterile Class III implantable medical device intended for intradermal/subdermal use.
  • For professional use only; must not be mixed with other products in the same syringe unless explicitly authorised by manufacturer protocol.

Packaging

  • Carton box containing 1 x 50 mg sterile lyophilised powder vial of JuveLook (PDLLA + HA).
  • Each vial is intended for single-patient, single-session use after reconstitution.
  • Outer packaging and vial label marked with product name, composition, batch/lot number and expiry date.
  • Supplied with instructions for use (IFU) and recommended reconstitution and injection protocol.
  • In some distribution channels, boxes of 10 vials are supplied for clinic/wholesale use (1 vial per inner unit).

Usage

  • For professional use only: JuveLook must be administered exclusively by qualified and experienced medical professionals trained in injectable biostimulators and facial anatomy.
  • Reconstitute the 50 mg lyophilised vial with 2–3 ml of sterile 0.9% saline (volume according to desired viscosity and manufacturer/clinic protocol). Allow sufficient time for complete hydration and gently swirl or use a mechanical mixer as recommended to obtain a homogeneous suspension; do not shake violently.
  • Inspect the vial after reconstitution to ensure no visible undissolved particles remain; if necessary, allow additional hydration time and gentle mixing until the suspension is uniform.
  • Transfer the reconstituted product to an appropriate sterile syringe using aseptic technique. Typical administration uses fine needles (e.g. 30G) or blunt cannulas (e.g. 25–27G) depending on treatment area and protocol.
  • Inject into the dermis or superficial subdermal plane depending on indication: micro-bolus, linear threading, or mesotherapy-style microinjections can be used in the face, periorbital region, neck or décolleté according to training.
  • Recommended treatment plan in many protocols: 2–3 sessions spaced 4–8 weeks apart for initial correction, with optional maintenance sessions approximately every 12–18 months thereafter, tailored to individual response.
  • Typical indications include tear troughs, infraorbital region, cheeks, temples, forehead, neck and décolleté; avoid overly superficial placement to reduce risk of visible particles and avoid deep intravascular injection.
  • Do not inject into or near blood vessels, or in areas with active infection, inflammation, or skin disease (e.g. active acne, herpes lesions, dermatitis).
  • After injection, mild massage of the treated area may be recommended in some protocols to distribute the product evenly, taking care to respect anatomical structures.
  • Post-treatment advice commonly includes avoiding intense heat (sun exposure, sauna, steam), vigorous exercise, alcohol excess and facial massage for 24–48 hours, and following local clinic-specific aftercare guidance.

Contraindications

  • Hypersensitivity or allergy to any component of the product, including Poly-D,L-lactic acid, hyaluronic acid or excipients.
  • Known history of severe allergic reactions or anaphylaxis unless carefully evaluated and deemed appropriate by the treating physician.
  • Active infection, inflammation or skin disease at or near the intended injection sites (e.g. active acne, herpes simplex, cellulitis or dermatitis).
  • Current or recent systemic infection, or significant immunosuppression, unless risk–benefit has been individually assessed.
  • Autoimmune diseases or connective tissue disorders without prior specialist evaluation and explicit approval, as biostimulators may theoretically modulate immune response.
  • Pregnancy or breastfeeding, as safety has not been established in these populations.
  • Patients under 18 years of age; JuveLook is intended for adult use only.
  • History of keloid or hypertrophic scar formation in the planned treatment area.
  • Presence of permanent fillers, foreign bodies or poorly vascularised scar tissue at the intended injection sites.
  • Bleeding disorders or current use of anticoagulant or antiplatelet medication that significantly increases bleeding risk, unless managed appropriately.
  • Known hypersensitivity to lidocaine or amide-type local anaesthetics if local anaesthetic cream or nerve blocks containing these agents are planned in conjunction with the procedure.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, mild pain or tenderness, itching, warmth and small bruises or haematomas; these typically resolve within a few days.
  • Temporary induration, firmness or palpable small nodules at injection points, usually improving as the product integrates and collagen remodelling progresses.
  • Asymmetry, over- or under-correction requiring adjustment at subsequent sessions.
  • Delayed-onset nodules or inflammatory reactions, which are uncommon but possible with any biostimulatory filler; may require medical management if persistent.
  • Infection at the injection site if aseptic technique is not strictly followed or if injected into contaminated tissue.
  • Very rare risk of vascular compromise if the suspension is inadvertently injected intravascularly, potentially leading to ischaemia and tissue damage; proper technique and aspiration where appropriate are essential to minimise this risk.
  • Transient oedema, especially in delicate areas such as under the eyes, which typically subsides within several days.
  • Hyperpigmentation or skin discolouration in predisposed individuals or following post-inflammatory changes.
  • Allergic or hypersensitivity reactions ranging from mild erythema to more pronounced inflammatory responses requiring medical evaluation.

Storage Conditions

  • Store at 2–25°C in a dry place, protected from direct light.
  • Do not freeze; freezing may alter the physical properties of the lyophilised powder and compromise safety or effectiveness.
  • Keep the vial in its original packaging until use to protect it from light and physical damage.
  • Do not use after the expiry date indicated on the packaging.
  • Single-use device: any unused reconstituted product must be discarded; do not re-sterilise or reuse.
  • Transport and store according to local regulations for temperature-sensitive medical devices, avoiding extreme temperature fluctuations.

Duration

Most clinical protocols report visible improvements in hydration and texture within weeks, with collagen-stimulating effects building over 2\u20133 months and overall results typically lasting around 12\u201318 months after a full course; some manufacturer and distributor data report durability up to approximately 24 months or more, with maintenance sessions recommended roughly every 12\u201324 months depending on skin condition and protocol.

Onset

Immediate to early: subtle plumping and hydration appear within days due to the non-crosslinked hyaluronic acid component, while PDLLA-driven neocollagenesis initiates over the following weeks, with progressive improvement in firmness, elasticity and texture generally observed from about 4\u20138 weeks onwards.

Browse more Skin booster / tissue stimulator

Top Treatments

Top Cities in the UK